Extracorporeal Shock Wave Therapy in Peyronie&apos;s Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study by di Mauro, Marina et al.
Received: Oct 29, 2018   Revised: Dec 22, 2018   Accepted: Jan 17, 2019   Published online Mar 26, 2019
Correspondence to: Giorgio Ivan Russo   https://orcid.org/0000-0003-4687-7353 
Urology Section, Department of Surgery, University of Catania, Via Santa Sofia 78, 95125, Catania, Italy.
Tel: +39-0953782710, E-mail: giorgioivan1987@gmail.com
Copyright © 2019 Korean Society for Sexual Medicine and Andrology
Original Article
pISSN: 2287-4208 / eISSN: 2287-4690
World J Mens Health Published online Mar 26, 2019
https://doi.org/10.5534/wjmh.180100 
Extracorporeal Shock Wave Therapy in Peyronie’s 
Disease: Clinical Efficacy and Safety from  
a Single-Arm Observational Study
Marina di Mauro1 , Giorgio Ivan Russo1 , Pier Andrea Della Camera2 , Fabrizio di Maida2 ,  
Gianmartin Cito2 , Nicola Mondaini3 , Marco Capece4 , Marco Falcone5 , Francesco Sessa2 ,  
Andrea Mari2 , Riccardo Campi2 , Carlotta Sabini2 , Sergio Serni2 , Mauro Gacci2 ,  
Andrea Minervini2 , Marco Carini2 , Sebastiano Cimino1 , Girolamo Morelli6 , Andrea Cocci2
1Urology Section, Department of Surgery, University of Catania, Catania, 2Department of Urology, University of Florence, 3Andrology 
Center, Villa Donatello Hospital, Florence, 4Department of Urology, University of Naples, Naples, 5Department of Urology, Molinette 
Hospital, University of Turin, Turin, 6Department of Urology, University of Pisa, Pisa, Italy
Purpose: In this study, we aimed to determine the role of extracorporeal shockwave therapy (ESWT) in the management of 
Peyronie’s disease (PD). 
Materials and Methods: A total of 325 patients suffering from PD were enrolled in this single-arm clinical study. All patients 
were received ESWT using a schedule of 1 treatment/wk. Penile curvature was measured by a goniometer after intracaverno-
sal drug-induced erection using Alprostadil. Plaque size was measured with a ruler and sexual function assessed by the inter-
national index of erectile function (IIEF)-15 score. Severity of erectile dysfunction was classified as severe (IIEF-15 ≤10), mod-
erate (IIEF-15 between 11 and 16), or mild (IIEF-15 between 17 and 25). Results were evaluated at baseline and 3 months 
after the treatment.
Results: All the patients completed the study protocol. Median age was 59.0 years (55.0–64.0 years). After treatment, the me-
dian (interquartile range, IQR) plaque size reduced from 1.78 cm2 (1.43–2.17 cm2) to 1.53 cm2 (1.31–1.96 cm2) (p<0.001); 
the median (IQR) penile length in erection increased from 13.0 cm (12.0–14.0 cm) to 14 cm (13.0–15.0 cm) (p<0.001) and 
the median (IQR) penile curvature from 30.4° (22.2°–35.4°) to 25.0° (20.2°–30.4°) (p<0.001). We also observed a decrease 
in pain assessed by visual analogue scale (7 vs. 3; p<0.001), an improvement in each of the IIEF sub-domains (p<0.001) and 
an improvement in all three PD questionnaire domains (p<0.001). 
Conclusions: Based on our findings, ESWT could be considered a safe and efficient minimally invasive option for the man-
agement of the patients suffering from PD.
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Peyronie’s disease (PD), also known as “induratio pe-
nis plastica”, is a superficial fibrous condition of the pe-
nis characterized by the presence of fibrotic plaques in 
the tunica albuginea causing pain, abnormal curvature 
and erectile dysfunction (ED) [1-5]. Moreover, it could 
be considered as a psychosocial disease since it affects 
the sexual life of the patient [6-8]. It typically affects 
males between the ages of 45 and 60 years [9]. Indeed, 
as described in literature, the mean reported age at 
disease presentation was 53.5 years [10]. Once thought 
to be rare, PD has a reported prevalence of up to 13.1% 
in adult men [11]. Nevertheless, the etiology of PD is 
not entirely understood, but is likely related to trauma 
followed by abnormal wound healing. Interestingly, the 
predisposition to fibrosis and abnormal wound healing 
might have a genetic basis in some affected men. It is 
important to note that most treatment methods have 
little evidence in the literature supporting their ef-
ficacy. Of the medications currently used, Collagenase 
Clostridium Hystoliticum (CCH) is the only Food and 
Drug Administration-approved drug for treatment of 
PD improving penile curvature and symptom bother. 
In this scenario, extracorporeal shockwave therapy 
(ESWT) represents an emergent minimally invasive 
approach. Despite several theories addressing the effect 
of lithotripters [12], these cannot be directly applied to 
understand the effect of shockwave on soft tissues. A 
regenerative potential of shockwave on several organs 
has been suggested, contrary to lithotripsy, which has 
a destructive impact on a urinary stone. In particular, 
ESWT may act by mechanical stimulation of cells [13], 
by stimulating synthesis of nitric oxide (NO), vascular 
endothelial growth factor (VEGF) and inducing angio-
genesis in the penile cavernous tissue. 
The aim of this single-arm was to evaluate the ef-
ficacy and safety of ESWT treatment in a large cohort 
of patients affected by PD. 
MATERIALS AND METHODS
From January 2016 to January 2018, we enrolled 325 
consecutive patients affected by PD in a multi-center 
single-arm clinical study. The study has been conducted 
according to the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) statement 
[14]. 
Patients with ≥18 years, active phase, and plaques 
and/or pain at erection and/or deviation were included 
in the study. 
Patients who have received previous intralesional 
therapy, oral drugs and patients without pain were ex-
cluded from the study.
All patients presented single plaque, evaluated at 
first by physical examination and subsequently by 
penile Doppler ultrasounds. All participants were 
adequately counselled and signed a detailed consent 
form prior to treatment and agreed to have their data 
anonymously utilized. All patients received ESWT 
(DUOLITH® SD1 ultra; STORZ MEDICAL AG, Täger-
wilen, Switzerland). The treatment was performed per-
pendicular on the penile shaft exactly on the top of the 
plaque with 1,500 pulses in the right side of the plaque 
and then 1,500 in the left side (3,000 hit at 0.25 mJ/
mm2). Each patient had 6 treatments, one treatment 
per week for six weeks.
Penile curvature was measured by a goniometer after 
intracavernosal drug-induces erection using Alprostadil 
(Viridal®; Schwarz Pharma, Monheim, Germany) and 
penile length during erection. Plaque size was mea-
sured with a ruler in cm2 using the ultrasound. Sexual 
function was assessed by the international index of 
erectile function (IIEF-15). Severity of ED was classi-
fied as severe (IIEF-15 ≤10), moderate (IIEF-15 between 
11 and 16), or mild (IIEF-15 between 17 and 25). The 
IIEF-15 sub-scores were assessed, including IIEF-erectile 
function (IIEF-EF), IIEF-orgasmic function (IIEF-OF), 
IIEF-sexual desire (IIEF-SD), IIEF-intercourse satisfac-
tion (IIEF-IS), and IIEF-overall satisfaction (IIEF-OS) 
[15]. Moreover, to measure the impact and severity of 
PD symptoms, patients were asked to fill out the PD 
questionnaire (PDQ). PDQ is a 15-question self-reported 
survey that measures the impact and severity of PD 
symptoms in three domains: psychological and physi-
cal symptoms (PS symptom severity score; PDQ ques-
tion 1–6), penile pain (penile pain score; PDQ question 
7–9), and symptom bother (bother score; PDQ question 
10–15). All patients completed the PDQ [16].
The results were evaluated at baseline and 3 months 
after the treatment. No other therapy for PD or ED 
was continued during this period. Phosphodiesterase 5 
inhibitors on demand (PDE-5i) were discontinued about 
3 weeks before the ESWT. In fact, as previously report-
ed, PDE-5i may act by the elevation of cyclic guanosine 
monophosphate levels and activation of protein kinase 
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G, which are involved in cell apoptosis and reducing 
collagen synthesis [8,17,18]. 
The patients continued to have their regular life-
style, sexual status, and other routine medications. 
Treatment emergent adverse events (TEAEs) were 
collected using self-reported events. The relation of 
adverse events to treatment was evaluated by the in-
vestigator based on the temporal relation to treatment 
and the likelihood of an alternative aetiology. 
1. Ethics statement
The study was conducted in accordance with Good 
Clinical Practice guidelines and the principles of the 
Declaration of Helsinki. Each patient signed a written 
informed consent to collect data. 
2. Statistical analysis
Continuous variables are presented as median and 
interquartile range (IQR) and were compared by the 
Student independent t-test or the Mann–Whitney U-
test based on their normal or not-normal distribution, 
respectively (normality of variables’ distribution was 
tested by the Kolmogorov–Smirnov test). Categorical 
variables were tested with the chi-square test. 
All statistical analyses were completed using Stata 
software, ver. 14 (StataCorp., College Station, TX, USA). 
For all statistical comparisons, a significance level of 
p<0.05 was considered to show differences between the 
groups. 
RESULTS
Table 1 lists the baseline characteristics of the study 
cohort. There were no dropouts, and the patients came 
for regular sessions and follow-up to complete question-
naires. Overall, median age of 59.0 years (IQR, 55.0–64.0 
years), median disease duration was 16.0 months (IQR: 
10.0–22.0 months), median plaque size was 1.78 cm2 
(IQR, 1.43–2.17 cm2), median penile length in erection 
was 13.0 cm, median penile curvature was 30.4° (IQR, 
22.2°–35.4°), median IIEF-EF was 14 (IQR, 11–16) and 
median PDQ was 13 (IQR, 11–17). The most common 
plaque site was in penile dorsum. As concerning comor-
bidities, 122 (37.5%) had diabetes and 140 (43.0%) hyper-
tension. 
After treatment, we observed a significant reduction 
of plaque size to 1.53 cm2 (IQR, 1.31–1.96 cm2) (p<0.001) 
of penile length to 14.0 cm (IQR, 13.0–15.0) (p<0.001). We 
also found a decrease of penile curvature to 25.0° (IQR, 
20.2°–30.4°) (p<0.001) and in visual analogue scale (VAS) 
from 7.0 (IQR, 7.0–8.0) to 3.0 (IQR, 3.0–6.0) (p<0.001). 
As concerning sexual function, the improvement in 
IIEF-15 was marked by an overall improvement in all 
the domains of IIEF: the median EF score, the median 
OF score, the median SD score, the median IS score, 
the median OS score (Table 2) (all p<0.001). There was 
an improvement in each of PDQ domains, clinically 
significant (p<0.001) (Table 2, Fig. 1). We also evaluated 
the correlation between duration of disease and mean 
difference of sexual questionnaires after treatment. 
We performed linear regression between VAS mean 
difference and IIEF-15 mean difference and we did not 
demonstrate significant association (r=-0.10; p=0.40). 
Table 1. Baseline characteristics of the population (n=325)
Variable Value
Age (y) 59.0 (55.0–64.0)
Age partner (y) 58.0 (54.0–61.0)
BMI (kg/m2) 24.0 (22.0–26.0)
Hypertension 140 (43.0)
Diabetes 122 (37.5)
Duration disease (mo) 16.0 (10.0–22.0)
Plaque size (cm2) 1.78 (1.43–2.17)
Penile length in erection (cm) 13.0 (12.0–14.0)
Penile curvature (°) 30.4 (22.2–35.4)
VAS 7.0 (7.0–8.0)
IIEF domain score
    IIEF total 14 (11–16)
    Erectile function 14 (11–16)
    Orgasmic function 5 (4–6)
    Sexual desire 5 (4–6)
    Intercourse satisfaction 9 (7–10)
    Overall satisfaction 5 (4–6)
Classification of ED
    Severe 58 (17.8)
    Moderate 194 (59.7)
    Mild 29 (8.9)
    None 44 (13.6)
PDQ score
    PDQ-PS 13 (11–17)
    PDQ-PP 7 (6–8)
    PDQ-BD 3 (3–4)
Values are presented as median (interquartile range) or number (%).
BMI: body mass index, VAS: visual analogue scale, IIEF: international 
index of erectile function, ED: erectile dysfunction, PDQ: Peyronie's 




The results are shown in Table 3. As it is possible to 
highlight, a longer duration of the disease correlates 
with a statistically significant improvement of sexual 
function. 
As concerning the presence of diabetes in our cohort, 
we verified the putative changes of all variables ac-
cording to the presence of diabetes. 
We observed a significant median increase of IIEF-IS 
(1.0 vs. 2.0; p=0.04) in diabetes while significant decrease 
of VAS in non-diabetics (-0.8 vs. -0.4 [standard devia-
tion, 1.33]; p=0.02). 
For the other variables, no significant changes were 
observed for PDQ-PS (p=0.48), PDQ-penile pain (p=0.33), 
PDQ-bother domain (p=0.68), plaque size (p=0.55), and 
penile curvature (p=0.72). 
We performed similar analysis for other risk factors, 
like hypertension or body mass index but we did not 
find significant differences for all variables. No TEAEs 
following ESWT were recorded. None of the patients in 
our study reported any allergic reaction to the gel used 
for ESWT. 
DISCUSSION
In the present study, we showed that ESWT treat-
ment is able to reduce objectively the severity of the 
disease and to improve sexual function in a group of 
patients suffering from PD. 
Recently, ESWT is gaining interest for the treat-
ment of PD and ED thanks to its mini-invasive char-
acteristics. Nevertheless, doubts still exist regarding 
the modality of application and its biological effects. 
Meta-analysis by Hauck et al [19] shows that decrease 
in plaque size was reported in 0% to 68% of cases, de-
Table 2. Characteristics of the patients after treatment
Characteristic Baseline Post-treatment p-value
Plaque size (cm2) 1.78 (1.43–2.17) 1.53 (1.31–1.96) <0.001
Penile length in erection (cm) 13.0 (12.0–14.0) 14.0 (13.0–15.0) <0.001
Penile curvature (°) 30.4 (22.2–35.4) 25.0 (20.2–30.4) <0.001
VAS 7.0 (7.0–8.0) 3.0 (3.0–6.0) <0.001
PDQ-PS 13 (11–17) 8 (6–12) <0.001
PDQ-PP 7 (6–8) 4 (2–6) <0.001
PDQ-BD 3 (3–4) 1 (1–3) <0.001
IIEF total 14 (11–16) 26 (23–27) <0.001
IIEF-erectile function 14 (11–16) 26 (23–27) <0.001
IIEF-orgasmic function 5 (4–6) 8 (7–8) <0.001
IIEF-sexual desire 5 (4–6) 7 (7–8) <0.001
IIEF-intercourse satisfaction 9 (7–10) 11 (10–12) <0.001
IIEF-overall satisfaction 5 (4–6) 8 (7–9) <0.001
Values are presented as median (interquartile range).
VAS: visual analogue scale, PDQ: Peyronie’s disease-questionnaire, PS: physical symptom, PP: penile pain, BD: bother domain, IIEF: international 
index of erectile function. 
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Fig. 1.  Median difference between 
questionnaires before and after treat-
ment. IIEF: international index of erectile 
function, OS: overall satisfaction, IS: in-
tercourse satisfaction, SD: sexual desire, 
OF: orgasmic function, EF: erectile func-
tion, TOT: tatal, PDQ: Peyronie’s disease-
questionnaire, BD: bother domain, PP: 
penile pain, PS: physical symptom, VAS: 
visual analogue scale.
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crease in curvature reported as no significant findings 
to 74% of cases and decrease in penile pain in 56% to 
100%. Sexual function, typically not clearly defined, im-
proved in 12% to 80%. These different results could be 
explained by the different groups of patients, modes of 
evaluation, techniques and study designs. But it should 
be noted that accurate measurement of plaque size is 
difficult with any imaging or mechanical modality. 
Moreover, results regarding plaques are difficult 
to interpret because plaque size reduction is not re-
ally a treatment aim, as penile deviation is the most 
troublesome symptom. In a randomized clinical trial 
from Palmieri et al [20], authors assumed that ESWT 
may have a protective effect on disease progression by 
stabilizing deviation and plaques. In another in a ran-
domized clinical trial [21] there are not reported ben-
efit respect to penile curvature, on the contrary to our 
results, which shows significant improvement in the 
subjective assessment of the penile curvature pre- and 
post-treatment (p<0.001). A meta-analysis from Gao et 
al [22] showed that ESWT could significantly increase 
the percentage of men with lessening of penile plaques 
(odds ratio [OR], 2.07), relief of pain (OR, 4.46), complete 
remission of pain (OR, 5.86), and slight differences for 
penile curvature (OR, 1.88; p=0.06), while no signifi-
cant differences for sexual function (OR, 2.22) between 
ESWT and placebo groups.
However, in this meta-analysis outcomes were ana-
lyzed dichotomously and not continuous while in our 
study they were analyzed continuously. In fact, we as-
sessed penile curvature in the erect state, with a slight 
improvement from median 30.4° (IQR: 22.2°–35.4°) at 
baseline to 25.0° (IQR: 20.2°–30.4°) post-treatment. 
Decreases in deviation in literature vary between 
21% and 74%. Hauck et al [23] found a significant re-
duction in the subgroup of patients with deviation of 
31° to 60° before ESWT. Mean deviation decreased from 
45.7° to 38.5° in this group. Like this, Palmieri et al [20] 
noted a significant reduction in deviation between the 
ESWT and placebo group (31° vs. 27°, respectively).
It is important to underline, that the impact of 
ESWT on PD is basically determined by pain relief. In 
fact, in our study, we showed to decreased from 7 to 4 
(VAS) but this effect did not influence IIEF-15 changes 
after treatment. Moreover, we also found that a longer 
duration of the disease was associated with statistically 
significant improvement of sexual function.
Many other previous studies have tried to attempt 
predictors of response in patients with PD [24,25], how-
ever data regarding outcomes after ESWT are lacking. 
A previous study from Cocci et al [6] in patients re-
ceiving CCH demonstrated that patients with longer 
PD duration, greater baseline penile curvature and 
basal and dorsal plaque location had a greater chance 
of treatment success in terms of penile curvature. 
Although our results are not comparable to these 
previous, we postulate that the longer the duration of 
the disease the most stable is PD. This may influence 
both restoring the sexual function considering both 
stabilization of curvature and also better psychological 
impact for the patients.
The mechanism of ESWT’s effect in PD is unclear, 
although satisfactory results were obtained from a lot 
of studies. ESWT may directly damage and remodel pe-
nile plaque. In fact, local circulation may be increased 
in consequence of generating heat caused by ESWT, 
which can result in an inflammatory reaction followed 
by increased macrophage activity, leading to plaque ly-
sis and resorption [26]. However, several discrepancies 
are present in the literature data that failed to drive 
specific recommendation about the clinical efficacy of 
ESWT. 
Previous literature data have reported that ESWT 
has a positive short-term clinical and physiological ef-
fect on the EF. In the randomized, double-blind, sham 
controlled study done by Vardi et al [27] ESWT has 
Table 3. Linear regression analysis between duration of the disease 
and mean difference of sexual questionnaires after treatment
Mean changes after ESWT Coefficient (95% CI) p-value
Plaque size -0.48 (-2.1–1.1) 0.55
Penile length in erection -0.2 (-0.9–0.51) 0.56
Penile curvature 0.02 (-0.07–0.1) 0.72
VAS score -0.09 (-0.28–0.09) 0.33
IIEF total 0.86 (0.73–0.98) <0.01 
IIEF-erectile function 0.99 (0.86–1.11) <0.01
IIEF-orgasmic function 2.99 (2.54–3.43) <0.01
IIEF-sexual desire 2.95 (2.49–3.42) <0.01
IIEF-intercourse satisfaction 1.71 (1.32–2.1) <0.01
IIEF-overall satisfaction 2.85 (2.39–3.30) <0.01
PDQ-PS -0.04 (-0.15–0.07) 0.48
PDQ-PP -0.08 (-0.24–0.08) 0.33
PDQ-BD -0.06 (-0.35–0.23) 0.68
ESWT, extracorporeal shockwave therapy, CI: confidence interval, 
VAS: visual analogue scale, IIEF: international index of erectile func-
tion, PDQ: Peyronie’s disease-questionnaire, PS: physical symptom, 
PP: penile pain, BD: bother domain. 
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been shown to have a beneficial effect on EF in men 
with PD. Protocol provided to receive 12 sessions of 
low intensity ESWT or sham therapy. Instead, open-
label single-arm prospective study by Gruenwald et 
al [28] shows that ESWT has a physiologic effect on 
the erectile mechanism and to improve IIEF-ED. The 
protocol was two treatment sessions per week for 3 
weeks, which were repeated after a 3-week no-treat-
ment interval. In the prospective, randomized, double-
blind, placebo-controlled study by Palmieri et al [20] 
it is shown that after 12 weeks VAS score, IIEF score 
ameliorated significantly in patients receiving ESWT. 
After 24 weeks plaque size and curvature degree were 
significantly reduced. Indeed, Palmieri et al [20] evalu-
ated that mean plaque size and mean curvature degree 
were significantly higher in the placebo group when 
compared with both baseline and ESWT values. Treat-
ment sessions were performed once weekly for four 
consecutive weeks. In agreement with the results in 
studies done by Vardi et al [27], Gruenwald et al [28] 
and Palmieri et al [20], we have found improvement in 
all the domains of IIEF and in the sexual function, re-
duction in VAS score, plaque size and penile curvature. 
Regarding VAS score, in our study it was reduced by 
4 points after treatment compared to baseline. In fact, 
the median VAS baseline was 7.0 (7.0–8.0) which im-
proved to 3.0 (3.0–6.0) post-treatment. This shows sta-
tistically significant (p<0.001) improvement in the pain 
score of patients’ post-treatment. 
ESWT may act by mechanical stimulation of cells 
[13,29], by stimulating synthesis of NO, VEGF and 
inducing angiogenesis in the penile cavernous tissue. 
Although this is out of the scope of our study, these 
premises could arise some questions about its role in 
patients with diabetes or hypertension. 
Although specific associations between diabetes, hy-
pertension and PD are difficult to arise, many reports 
found positive link [30,31]. The diabetes might condition 
the gravity of the disease because it would worsen the 
micro-circulation of penis and determine a considerable 
fibrotic process due to disease. 
Blood hypertension is shown to be differently associ-
ated to PD, even though the etiological and pathophys-
iological factors of this association is unknown. A case-
cohort study from Pavone et al [32] showed that among 
patients with blood hypertension PD was diagnosed in 
69 patients (44%) and that among patients with nor-
mal blood pressure it was diagnosed in 28 patients (23%) 
(p<0.001).
Our favorable results, in fact, maybe also justified by 
the high prevalence of diabetes in our cohort, that can 
benefit from the ESWT activity in terms of improving 
micro-circulation. 
We would also point out that our favorable findings 
about plaque size and penile curvature improvement 
are difficult to transfer into clinical practice. In fact, 
patients may not be aware of such improvement. On 
the contrary, pain and sexual function increase repre-
sent the main patient reported outcomes after ESWT. 
For these reasons, we support translation of our re-
sults into clinical practice for several aspects. ESWT 
represents a valuable treatment for PD patients, ame-
liorating penile curvature, EF, plaque size, and pain 
resolution. Although we are cannot did not compare 
different energy source delivering, our protocol was 
demonstrated to be reliable and efficient. 
Some limitations of this study should be addressed. 
This is a single arm non-randomized clinical trial to 
evaluate the benefits of ESWT in the management of 
PD. Furthermore, the open label design without control 
may have influenced clinical outcomes. Finally, the 3 
weeks of dropout from PDE-5i should be considered 
when evaluating our clinical outcomes. The study is 
feasible for the availability of the ESWT machine and 
because are not necessarily special skills. However, 
more randomized controlled trials studies should be 
performed to make ESWT a valid procedure. A longer 
follow-up period would also serve to gain a better un-
derstanding of the potential limitations of the therapy. 
CONCLUSIONS
ESWT represents a new reality for men’s health and 
a new weapon for the uro-andrologist, focusing on the 
mechanism of inducing angiogenesis in the penile cav-
ernous tissue. Moreover, it offers a safe and efficient 
minimally invasive option in the management of the 
patients with PD, in particular when they not respond 
to the conservative treatment, before resorting to sur-
gery. 
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